758 results on '"Sculpher, Mark"'
Search Results
2. System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework
3. A qualitative study on the feasibility and acceptability of institutionalizing health technology assessment in Malawi
4. Using Age-Specific Values for Pediatric HRQoL in a Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
5. The Lancet Commission on prostate cancer: planning for the surge in cases
6. Abstract 16635: Cost Effectiveness Analysis of the Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction REVIVED Trial Data
7. Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol
8. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?
9. Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies
10. Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
11. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
12. Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa
13. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
14. Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required.
15. Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy
16. The Use of MCDA in HTA: Great Potential, but More Effort Needed
17. Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers
18. Common Methodological Flaws in Economic Evaluations
19. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
20. Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions
21. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial.
22. Economic evaluation of self-help group interventions for health in LMICs: a scoping review.
23. Building Uncertainty into Cost-Effectiveness Rankings: Portfolio Risk-Return Tradeoffs and Implications for Decision Rules
24. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought
25. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
26. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial
27. Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
28. The HOME Study: study protocol for a randomised controlled trial comparing the addition of Proactive Psychological Medicine to usual care, with usual care alone, on the time spent in hospital by older acute hospital inpatients
29. Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
30. Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial
31. Reforming the Cancer Drug Fund
32. Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms
33. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial
34. Should the Lambda (λ) Remain Silent?
35. The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure
36. Understanding Harris' understanding of CEA: is cost effective resource allocation undone?
37. ISPOR’s Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics
38. Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis
39. Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
40. Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions
41. The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS)
42. Determinants of the Cost of Health Services Used by Veterans With HIV
43. An Economic Model For The Prevention Of MRSA Infections After Surgery: Non-Glycopeptide Or Glycopeptide Antibiotic Prophylaxis?
44. Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery
45. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost-effectiveness study
46. Decision analysis for resource allocation in health care
47. Value Based Pricing for NHS Drugs: An Opportunity Not to Be Missed?
48. Not so...
49. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence
50. Is self-care a cost-effective use of resources? Evidence from a randomized trial in inflammatory bowel disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.